Elutia's earnings call highlighted significant progress and strategic realignments, including the sale of its bioenvelope business, growth in key product lines, and improved financial metrics. However, challenges remain with a decline in overall sales, historical revenue declines in SimpliDerm, and ongoing litigation liabilities.

Company Guidance

During the call, Elutia provided several key metrics and guidance related to its operations and future plans. The company announced the sale of its bioenvelope business to Boston Scientific for $88 million in cash, enhancing its financial position with approximately $49 million post-expenses and debt payoff. This transaction also validates Elutia's technology platform, which the company plans to leverage for its new NXT-41x product aimed at the $1.5 billion breast reconstruction market. The company highlighted its previous success with EluPro, achieving an $18 million run rate within nine months of launch, and aims to replicate or exceed this with NXT-41x. Elutia now has full control over its SimpliDerm and cardiovascular product lines, which are expected to bolster the commercial infrastructure ahead of NXT-41x's rollout. Financially, the company reported a 64% adjusted gross margin for continuing operations and a $2.7 million adjusted EBITDA loss for the quarter. The company is optimistic about its path to market, supported by its enhanced balance sheet and operational efficiencies gained from the business divestiture.

Sale of Bioenvelope Business

Elutia successfully sold its bioenvelope business, including EluPro and CanGaroo products, to Boston Scientific for $88 million in cash. This transaction validates Elutia's technology platform and transforms its balance sheet.

SimpliDerm Revenue Growth

SimpliDerm generated $2.4 million in revenue, marking an increase of 18% from Q2 2025. The company regained full control over the product line after ending a distribution partnership.

Cardiovascular Segment Performance

The cardiovascular segment saw its first full quarter of direct sales with revenue reaching just under $1.9 million, a 68% increase from the previous year and a 28% sequential increase.

Improved Gross Margins

GAAP gross margin improved to 55.8% from 49% a year ago, and adjusted gross margin increased to 64% from 56% in the same period.

Reduction in Operating Expenses

Operating expenses decreased to $7.1 million from $11 million a year ago, contributing to a reduced loss from operations of $5.2 million compared to $9 million in the prior year.

Progress in Litigation

Elutia resolved 7 more FiberCel litigation cases, reducing the total from 110 to just 6 remaining cases.

Aziyo Biologics (ELUT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ELUT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 04, 2026	2025 (Q4)	-0.12 / -	-0.26	―	―	―
Nov 06, 2025	2025 (Q3)	-0.15 / -0.19	-0.33	42.42% (+0.14)
Aug 14, 2025	2025 (Q2)	-0.17 / -0.26	-1.14	77.19% (+0.88)
May 08, 2025	2025 (Q1)	-0.20 / -0.21	-0.75	72.00% (+0.54)
Mar 06, 2025	2024 (Q4)	-0.25 / -0.26	-0.66	60.61% (+0.40)
Nov 14, 2024	2024 (Q3)	-0.44 / -0.33	-0.5	34.00% (+0.17)
Aug 07, 2024	2024 (Q2)	-0.33 / -1.14	-0.65	-75.38% (-0.49)
May 09, 2024	2024 (Q1)	-0.41 / -0.75	-0.49	-53.06% (-0.26)
Mar 07, 2024	2023 (Q4)	-0.28 / -0.66	-0.38	-73.68% (-0.28)
Nov 13, 2023	2023 (Q3)	-0.55 / -0.50	-0.73	31.51% (+0.23)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ELUT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2025	$0.94	$0.90	-4.26%
Aug 14, 2025	$2.15	$2.02	-6.05%
May 08, 2025	$1.99	$2.08	+4.52%
Mar 06, 2025	$2.55	$2.78	+9.02%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Aziyo Biologics (ELUT) report earnings?

Aziyo Biologics (ELUT) is schdueled to report earning on Mar 04, 2026, After Close (Confirmed).

What is Aziyo Biologics (ELUT) earnings time?

Aziyo Biologics (ELUT) earnings time is at Mar 04, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ELUT EPS forecast?

ELUT EPS forecast for the fiscal quarter 2025 (Q4) is -0.12.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing